The Effect of UrsodeoXyCholicacid (UDCA) and ezetimibe on total faecal steRol ExcreTion and plasma lipid lEvels

Trial Profile

The Effect of UrsodeoXyCholicacid (UDCA) and ezetimibe on total faecal steRol ExcreTion and plasma lipid lEvels

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Ezetimibe (Primary) ; Ursodeoxycholic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms EXCRETE
  • Most Recent Events

    • 29 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top